1-2 of 2
Josep Borras
Close
Sort by
Journal Articles

Mutational Studies Using Next Generation Sequencing in High Risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients Treated with Azacitidine (High risk MDS 2009 protocol from CETLAM Group)

Marta Cabezon, Joan Bargay, MD PhD, Blanca Xicoy, MD PhD, Laura Palomo, MSc, Sílvia Marcé, PhD, Ramón Guàrdia, MD PhD, Salut Brunet, MD PhD, Carmen Pedro, MD PhD, Mar Tormo, MD PhD, Vera Ademà, MSc, Victor Marco, Lourdes Escoda, MD PhD, Llorenç Font, MD PhD, Elena Rámila, MD PhD, Josep Maria Martí, MD PhD, David Valcarcel, MD PhD, Josep Borras, Evarist Feliu, MD PhD, Fuensanta Millá, MD PhD, Lurdes Zamora, PhD
Journal: Blood
Blood (2015) 126 (23): 2905.
https://doi.org/10.1182/blood.V126.23.2905.2905
Published: 2015
Journal Articles

Methylation Patterns in Patients with High-Risk Myelodysplatic Syndromes and Secondary Acute Myeloid Leukemia Treated with Azacitidine (high-risk MDS 2009 protocol from CETLAM Group)

Marta Cabezón, Yulia Medvedeva, PhD, Joan Bargay, MD PhD, Blanca Xicoy, MD PhD, Sílvia Marcé, PhD, Ramon Guàrdia, MD PhD, Salut Brunet, MD PhD, Carmen Pedro, MD PhD, Mar Tormo, MD PhD, Victor Marco, Lourdes Escoda, MD PhD, Llorenç Font, MD PhD, Elena Rámila, MD PhD, David Valcárcel, MD PhD, Josep Maria Martí, MD PhD, Josep Borras, Evarist Feliu, MD PhD, Fuensanta Millá, MD PhD, Tanya Vavouri, PhD, Lurdes Zamora, PhD
Journal: Blood
Blood (2015) 126 (23): 1682.
https://doi.org/10.1182/blood.V126.23.1682.1682
Published: 2015